The International Communication Effectiveness of China’s Image from the Perspective of Soft Power Pillars: A Case Study of ...
Introduction The transition from clinical practice to an academic role presents a multifaceted challenge for anaesthesia master’s students in Iran, as it demands not only clinical expertise but also ...
The paperwork burden of prior authorization keeps climbing, and for some ASCs, the only way through is to treat it like a daily fight. Elisa Auguste, administrator at East Setauket, N.Y.-based ...
Strategy's crypto treasury model involves selling new stock and issuing debt in order to raise funds to buy more Bitcoin. The stock will likely outperform Bitcoin if the token rallies, but shares ...
The kidney's proximal tubule reabsorbs water, glucose, ions and other small molecules from the urine and thus maintains the body's supply of these essential constituents. The tubule can be easily ...
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors. This manuscript used ...
Inflammation has to fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center (DKFZ) have now deciphered in more detail how the organism masters this ...
Popular vibe coding platforms consistently generate insecure code in response to common programming prompts, including creating vulnerabilities rated as ‘critical,’ new testing has found. Security ...
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also ...
On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...
The MarketWatch News Department was not involved in the creation of this content. TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics, a clinical-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results